We believe that objective assessment of visual function with tests like SD-tVEP will bring to the general ophthalmologist a more reliable way to diagnose the early stages of diseases that affect the optic nerve.
Pine Brook, NJ (PRWEB) January 03, 2013
A new article published in a recent edition of Ocular Surgery News shows a new visual evoked potential (VEP) technique to be an easy, objective method to screen for functional damage in glaucomatous eyes. The technique within the Diopsys® NOVA-LX software, called short duration transient VEP (SD-tVEP), provides an automated interpretation which enhances the reliability and reproducibility of the results and provides less subjectivity in evaluating results compared to traditional VEP methods. The article highlights a study carried out at New York Eye and Ear Infirmary (New York, NY) called “Short Duration Transient Visual Evoked Potentials in Glaucomatous Eyes.” The researchers investigated the correlation between structural and functional damage in glaucoma patients.
Early detection of glaucoma remains difficult despite the many different devices found in an ophthalmologist or optometrist’s office. Functional damage from glaucoma is often assessed by a subjective and often unreliable method known as a visual field test that requires a patient to react physically to a series of lights. The SD-tVEP results in the study correlated significantly with the severity of visual field damage, but the VEP results were obtained objectively.
Ocular Surgery News quotes study co-author, Celso Tello, MD, as saying, “SD-tVEP is especially useful in patients in whom subjective assessment with Humphrey visual fields are not reliable or because they perform poorly on these tests for various reasons, such as physical limitations or poor test-taking ability. We believe that objective assessment of visual function with tests like SD-tVEP will bring to the general ophthalmologist a more reliable way to diagnose the early stages of diseases that affect the optic nerve.” In addition, in eyes with advanced glaucoma, poor VEP results were associated with decreased macular thickness on OCT, indicating a structural correlation as well.
Dr. Tello also mentions that he and colleagues will study a new pattern ERG software module that will be an add-on to existing Diopsys® NOVA devices, the Diopsys® NOVA-pERG. This module will allow eye care specialists to isolate retinal ganglion cell loss. Dr. Tello says that combining the SD-tVEP and pERG results will provide a significant improvement in the assessment of visual pathway diseases.
Diopsys, Inc. (http://www.diopsys.com/) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing electrophysiological technology, including Visual Evoked Potential (VEP) technology.
Diopsys has developed and markets the patented Diopsys® NOVA-VEP Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders, including glaucoma. Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including amblyopia, in children as young as six months of age.